Furthermore, advancements in understanding the tumor microenvironment have revealed that histone deacetylase (HDAC) inhibitor chidamide may emerge as a potentially beneficial agent for AITL patients. Here, HDAC9 is linked to angioimmunoblastic T-cell lymphoma.